During stem cell mobilization all patients received meloxicam to enhance stem cell mobilization and ondansetron as prophylactic antiemetic therapy. Sulfamethoxazole-trimethoprim was given as prophylaxis for pneumocystis jiroveci infection from the start of HDCT until 3 weeks after ASCT. Fluconazol was administered from HDCT until the end of aplasia to prevent fungal infections, and valaciclovir as virostatic prophylaxis from day +1 until 3 months post-ASCT. Dexamethasone was given from day −4 to ASCT and from day +9 to +13 after ASCT as prophylaxis of engraftment syndrome. Antiallergic prophylaxis before ASCT was performed with iv methylprednisolone and clemastine. Allopurinol was given to prevent tumor lysis syndrome during HDCT. Additionally, after ASCT all patients received folic acid for 8 weeks to improve hematopoietic recovery. Zoledronic acid was given at day +1 after ASCT. All patients received G-CSF (filgrastim) 5 μg/kg/day from day +6 to +12 after ASCT. Further supportive medication included aprepitant, ondansetron, esomeprazole, enoxaparin natrium and furosemide.
Free full text: Click here